Loading...
Market
Story
FDA Approves Rybrevant for EGFR-Mutated Lung Cancer in US, Reducing Progression Risk by Over 50%
Sep 20, 2024, 09:56 AM
Rybrevant (amivantamab-vmjw) has been approved by the FDA for the treatment of second-line EGFR-mutated advanced lung cancer in the US. This approval marks the first and only targeted regimen to cut the risk of disease progression by more than 50% when used in combination with standard care. This significant development is expected to help Johnson & Johnson move closer to its $5 billion sales target for Rybrevant. The approval specifically applies to patients with EGFR ex19del/L858R substitution mutations who have progressed on or after EGFR TKI treatment. Notably, this is the third new indication for Johnson & Johnson in 2024.
View original story
Similar markets
None • 25%
One • 25%
Two • 25%
Three or more • 25%
Less than 10 • 25%
10-20 • 25%
21-30 • 25%
More than 30 • 25%
Lung cancer related indication • 25%
Other cancer indication • 25%
Non-cancer indication • 25%
No new approval • 25%
Less than $2 billion • 25%
$2 billion to $3 billion • 25%
$3 billion to $4 billion • 25%
More than $4 billion • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
More than $2 billion • 25%
Japan • 25%
Canada • 25%
Australia • 25%
None of the above • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
None • 25%
1 additional indication • 25%
2 additional indications • 25%
3 or more additional indications • 25%